• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肺动脉高压协会注册研究的基础结果:与年龄相关的肺高血压血液动力学和功能状态的差异。

Age-related differences in hemodynamics and functional status in pulmonary arterial hypertension: Baseline results from the Pulmonary Hypertension Association Registry.

机构信息

Department of Medicine, University of California, San Francisco, San Francisco, California.

Department of Medicine, University of California, San Francisco, San Francisco, California.

出版信息

J Heart Lung Transplant. 2020 Sep;39(9):945-953. doi: 10.1016/j.healun.2020.05.005. Epub 2020 May 16.

DOI:10.1016/j.healun.2020.05.005
PMID:32507341
Abstract

BACKGROUND

The age of patients with pulmonary arterial hypertension (PAH) has increased, with registries now reporting mean ages of 50 to 65 years old. Limited data exist on age-related differences in hemodynamic and functional assessments in PAH.

METHODS

Adults with PAH in the Pulmonary Hypertension Association Registry were divided into 3 groups (18-50, 51-65, and >65 years old). Analysis of variance and chi-square testing were used to assess for baseline differences. Linear regression was used to examine the association of age with continuous hemodynamic and functional variables.

RESULTS

A total of 769 patients with mean age of 56 ± 16 years were included. Older patients had more connective tissue disease-associated PAH and less drug-associated PAH. In linear regression models, each year of increased age was associated with shorter 6-minute walk distance (-3.37 meters; 95% CI, -3.97 to -2.76), lower mean pulmonary arterial pressure (-0.21 mm Hg; 95% CI, -0.27 to -0.15), and lower pulmonary vascular resistance (-0.06 Wood units; 95% CI, -0.09 to -0.04). Pulmonary arterial compliance, cardiac index, right ventricular stroke work index, and percent predicted 6-minute walk distance were unrelated to age; resistance-compliance time was negatively related to age (-3 milliseconds per year; 95% CI, -4 to -2).

CONCLUSIONS

Relative to their pulmonary vascular resistance, older patients have lower pulmonary artery compliance and worse right ventricular performance. Based on these findings, we suspect that age influences right ventricular loading conditions and the response of the right ventricle to increased afterload.

摘要

背景

肺动脉高压(PAH)患者的年龄有所增加,注册研究报告的平均年龄为 50 至 65 岁。关于 PAH 中与年龄相关的血流动力学和功能评估的相关数据有限。

方法

将肺动脉高压协会登记处中的成年 PAH 患者分为 3 组(18-50 岁、51-65 岁和>65 岁)。采用方差分析和卡方检验评估基线差异。采用线性回归检验年龄与连续血流动力学和功能变量的相关性。

结果

共纳入 769 例平均年龄为 56 ± 16 岁的患者。年龄较大的患者患有更多的结缔组织疾病相关 PAH 和较少的药物相关 PAH。在线性回归模型中,每增加 1 岁,6 分钟步行距离减少 3.37 米(95%CI,-3.97 至-2.76),平均肺动脉压降低 0.21mmHg(95%CI,-0.27 至-0.15),肺血管阻力降低 0.06 伍德单位(95%CI,-0.09 至-0.04)。肺动脉顺应性、心指数、右心室每搏功指数和 6 分钟步行距离预测百分比与年龄无关;阻力-顺应性时间与年龄呈负相关(每年减少 3 毫秒;95%CI,-4 至-2)。

结论

与肺动脉阻力相比,年龄较大的患者肺动脉顺应性较低,右心室功能更差。基于这些发现,我们怀疑年龄会影响右心室的负荷条件以及右心室对后负荷增加的反应。

相似文献

1
Age-related differences in hemodynamics and functional status in pulmonary arterial hypertension: Baseline results from the Pulmonary Hypertension Association Registry.肺动脉高压协会注册研究的基础结果:与年龄相关的肺高血压血液动力学和功能状态的差异。
J Heart Lung Transplant. 2020 Sep;39(9):945-953. doi: 10.1016/j.healun.2020.05.005. Epub 2020 May 16.
2
Prognostic Value of Follow-Up Hemodynamic Variables After Initial Management in Pulmonary Arterial Hypertension.初始治疗后随访血流动力学变量对肺动脉高压的预后价值。
Circulation. 2018 Feb 13;137(7):693-704. doi: 10.1161/CIRCULATIONAHA.117.029254. Epub 2017 Oct 25.
3
Four- and seven-year outcomes of patients with congenital heart disease-associated pulmonary arterial hypertension (from the REVEAL Registry).先天性心脏病相关肺动脉高压患者的 4 年和 7 年结局(来自 REVEAL 登记研究)。
Am J Cardiol. 2014 Jan 1;113(1):147-55. doi: 10.1016/j.amjcard.2013.09.032. Epub 2013 Oct 4.
4
Investigating the "sex paradox" in pulmonary arterial hypertension: Results from the Pulmonary Hypertension Association Registry (PHAR).研究肺动脉高压中的“性别悖论”:来自肺动脉高压协会注册中心(PHAR)的结果。
J Heart Lung Transplant. 2024 Jun;43(6):901-910. doi: 10.1016/j.healun.2024.02.004. Epub 2024 Feb 13.
5
Predictive Value of Pulmonary Arterial Compliance in Systemic Lupus Erythematosus Patients With Pulmonary Arterial Hypertension.肺动脉顺应性对系统性红斑狼疮肺动脉高压患者的预测价值。
Hypertension. 2020 Oct;76(4):1161-1168. doi: 10.1161/HYPERTENSIONAHA.120.15682. Epub 2020 Aug 10.
6
Pulsatile haemodynamic parameters are predictors of survival in paediatric pulmonary arterial hypertension.脉动血流动力学参数可预测儿科肺动脉高压患者的生存情况。
Int J Cardiol. 2013 Sep 30;168(2):1370-7. doi: 10.1016/j.ijcard.2012.12.080. Epub 2013 Jan 20.
7
Differences in pulmonary arterial flow hemodynamics between children and adults with pulmonary arterial hypertension as assessed by 4D-flow CMR studies.通过4D流CMR研究评估的儿童和成人肺动脉高压患者之间的肺动脉血流动力学差异。
Am J Physiol Heart Circ Physiol. 2019 May 1;316(5):H1091-H1104. doi: 10.1152/ajpheart.00802.2018. Epub 2019 Mar 1.
8
Hemodynamic Response to Treatment and Outcomes in Pulmonary Hypertension Associated With Interstitial Lung Disease Versus Pulmonary Arterial Hypertension in Systemic Sclerosis: Data From a Study Identifying Prognostic Factors in Pulmonary Hypertension Associated With Interstitial Lung Disease.特发性肺纤维化相关肺动脉高压与系统性硬化症相关肺动脉高压患者治疗后血流动力学反应及结局比较:特发性肺纤维化相关肺动脉高压预后因素研究数据。
Arthritis Rheumatol. 2021 Feb;73(2):295-304. doi: 10.1002/art.41512. Epub 2020 Dec 29.
9
Sex differences in hemodynamic responses and long-term survival to optimal medical therapy in patients with pulmonary arterial hypertension.肺动脉高压患者血流动力学反应及对最佳药物治疗长期生存的性别差异。
Heart Vessels. 2018 Aug;33(8):939-947. doi: 10.1007/s00380-018-1140-6. Epub 2018 Feb 13.
10
Clinical Differences and Outcomes between Methamphetamine-associated and Idiopathic Pulmonary Arterial Hypertension in the Pulmonary Hypertension Association Registry.在肺动脉高压协会注册中心,与甲基苯丙胺相关的特发性肺动脉高压的临床差异和结局。
Ann Am Thorac Soc. 2021 Apr;18(4):613-622. doi: 10.1513/AnnalsATS.202007-774OC.

引用本文的文献

1
Effects of macitentan and selexipag across prognostic age groups in patients with pulmonary arterial hypertension.马昔腾坦和司来帕格在不同预后年龄组肺动脉高压患者中的作用。
JHLT Open. 2025 Jan 16;7:100197. doi: 10.1016/j.jhlto.2024.100197. eCollection 2025 Feb.
2
Genetics and precision genomics approaches to pulmonary hypertension.遗传学和精准基因组学在肺动脉高压中的应用。
Eur Respir J. 2024 Oct 31;64(4). doi: 10.1183/13993003.01370-2024. Print 2024 Oct.
3
Risk stratification and treatment goals in pulmonary arterial hypertension.
肺动脉高压的风险分层和治疗目标。
Eur Respir J. 2024 Oct 31;64(4). doi: 10.1183/13993003.01323-2024. Print 2024 Oct.
4
Investigating the "sex paradox" in pulmonary arterial hypertension: Results from the Pulmonary Hypertension Association Registry (PHAR).研究肺动脉高压中的“性别悖论”:来自肺动脉高压协会注册中心(PHAR)的结果。
J Heart Lung Transplant. 2024 Jun;43(6):901-910. doi: 10.1016/j.healun.2024.02.004. Epub 2024 Feb 13.
5
Real-world evidence to advance knowledge in pulmonary hypertension: Status, challenges, and opportunities. A consensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative's Real-world Evidence Working Group.推进肺动脉高压知识的真实世界证据:现状、挑战与机遇。肺血管研究所创新药物开发倡议真实世界证据工作组的共识声明。
Pulm Circ. 2023 Dec 21;13(4):e12317. doi: 10.1002/pul2.12317. eCollection 2023 Oct.
6
Can Pulmonary Arterial Compliance Be a Prognostic Marker for Pulmonary Hypertension?肺动脉顺应性能否作为肺动脉高压的预后标志物?
Am J Respir Crit Care Med. 2023 Oct 1;208(7):822-823. doi: 10.1164/rccm.202306-1076LE.
7
Health Care Disparities in Pulmonary Arterial Hypertension.肺动脉高压中的医疗保健差异。
Clin Chest Med. 2023 Sep;44(3):543-554. doi: 10.1016/j.ccm.2023.03.010. Epub 2023 May 23.
8
Cardiometabolic Risk Factors Associated With Right Ventricular Function and Compensation in Patients Referred for Echocardiography.与超声心动图检查患者右心室功能和代偿相关的心脏代谢危险因素。
J Am Heart Assoc. 2023 Jun 20;12(12):e028936. doi: 10.1161/JAHA.122.028936. Epub 2023 Jun 10.
9
On errata and corrigenda-The Pulmonary Hypertension Association Registry (PHAR).关于勘误和更正——肺动脉高压协会注册库(PHAR)。
Pulm Circ. 2022 Jul 1;12(3):e12131. doi: 10.1002/pul2.12131. eCollection 2022 Jul.
10
Effects of oral targeted treatments in pulmonary arterial hypertension: A systematic review and meta-analysis.口服靶向治疗对肺动脉高压的影响:一项系统评价与荟萃分析。
Front Cardiovasc Med. 2022 Aug 2;9:915470. doi: 10.3389/fcvm.2022.915470. eCollection 2022.